Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.40 |
| ▸ | RPLP1 | P05386 | 6/20 | 0.38 |
| ▸ | RPLP0 | P05388 | 6/20 | 0.38 |
| ▸ | RPS17 | P08708 | 6/20 | 0.38 |
| ▸ | RPSA | P08865 | 6/20 | 0.38 |
| ▸ | RPS2 | P15880 | 6/20 | 0.38 |
| ▸ | RPL35A | P18077 | 6/20 | 0.38 |
| ▸ | RPL7 | P18124 | 6/20 | 0.38 |
| ▸ | RPL17 | P18621 | 6/20 | 0.38 |
| ▸ | RPS4Y1 | P22090 | 6/20 | 0.38 |
| ▸ | RPS3 | P23396 | 6/20 | 0.38 |
| ▸ | RPS12 | P25398 | 6/20 | 0.38 |
| ▸ | RPL13 | P26373 | 6/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29586328 | 1.00 | DDB1 (0.43) | DDB1CRBNNPC1ALDH1A1MAPT | |
| SCHEMBL31098985 | 0.75 | MEN1 (0.45) | NPC1ALDH1A1RAB9ASMN1; SMN2KCNH2 | |
| SCHEMBL29587147 | 0.75 | DPP8 (0.42) | NPC1ALDH1A1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL21047600 | 0.75 | DPP8 (0.42) | NPC1ALDH1A1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL31098988 | 0.73 | SLC6A2 (0.45) | DDB1CRBNKCNH2RPLP1RPLP0 | |
| SCHEMBL21047735 | 0.72 | HTR1A (0.38) | ALDH1A1 | |
| SCHEMBL21047678 | 0.72 | DDB1 (0.44) | DDB1CRBNNPC1ALDH1A1MAPT | |
| SCHEMBL29586754 | 0.72 | DDB1 (0.44) | DDB1CRBNNPC1ALDH1A1MAPT | |
| SCHEMBL21047679 | 0.71 | UTS2R (0.45) | DDB1CRBNNPC1ALDH1A1MAPT | |
| SCHEMBL21047726 | 0.71 | HCRTR1 (0.47) | DDB1CRBNNPC1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3495341-B1 | PREPARATION PROCESS OF PERFLUOROALKYL COMPOUND WITH MONOHYDROPERFLUOROALKANE AS STARTING MATERIAL | KANTO DENKA KOGYO KK (JP) | 2022-11-02 | — | — | EP | disclosed |
| US-10450253-B2 | Preparation process of perfluoroalkyl compound with monohydroperfluoroalkane as starting material | KANTO DENKA KOGYO CO., LTD. (JP) | 2019-10-22 | — | — | US | disclosed |
| EP-3495341-A1 | METHOD FOR PRODUCING PERFLUOROALKYL COMPOUND USING MONOHYDROPERFLUOROALKANE AS STARTING MATERIAL | Kanto Denka Kogyo Co., Ltd. (JP) | 2019-06-12 | — | — | EP | disclosed |
| US-20190169107-A1 | PREPARATION PROCESS OF PERFLUOROALKYL COMPOUND WITH MONOHYDROPERFLUOROALKANE AS STARTING MATERIAL | NATIONAL UNIVERSITY CORPORATION GUNMA UNIVERSITY (JP) | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190169107-A1 | PREPARATION PROCESS OF PERFLUOROALKYL COMPOUND WITH MONOHYDROPERFLUOROALKANE AS STARTING MATERIAL | PFKFB1, PFKFB4, PFAS | DDB1 4487/4885CRBN 1845/4885NPC1 1884/4885 |
| US-10450253-B2 | Preparation process of perfluoroalkyl compound with monohydroperfluoroalkane as starting material | PFKFB1, PFKFB4, PFAS | DDB1 4487/4885CRBN 1845/4885NPC1 1884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.